The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma

Pulmonary Pharmacology and Therapeutics

Volumn 39, Issue , 2016, Pages 54-63

  Erpenbeck, Veit J ^a   Popov, Todor A ^b   Miller, David ^c   Weinstein, Steven F ^d   Spector, Sheldon ^e   Magnusson, Baldur ^a   Osuntokun, Wande ^f   Goldsmith, Paul ^f   Weiss, Markus ^a   Beier, Jutta ^g  

^a NOVARTIS PHARMA AG   (Switzerland)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c NEMRA   (United States)

^d Allergy and Asthma Specialists Medical Group and Research Center   (United States)

^e California Allergy and Asthma Medical Group Inc   (United States)

^f Novartis Pharma   (United Kingdom)

^g Institut fur Atemwegsforschung INSAF   (Germany)

Author keywords

Asthma; Chemoattractant receptor homologous molecule expressed on Th2 cells; Clinical trial

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CREATINE KINASE; FEVIPIPRANT; NITRIC OXIDE; TRIACYLGLYCEROL LIPASE; ANTIASTHMATIC AGENT; IMMUNOGLOBULIN RECEPTOR; INDOLEACETIC ACID DERIVATIVE; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; PYRIDINE DERIVATIVE;

ADULT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BRADYCARDIA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MUSCLE SPASM; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY AIRFLOW; SOMNOLENCE; TH2 CELL; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ANTAGONISTS AND INHIBITORS; ASTHMA; CLINICAL TRIAL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDOLEACETIC ACIDS; MALE; MIDDLE AGED; PYRIDINES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; TREATMENT OUTCOME;

EID: 84979210470     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2016.06.005     Document Type: Article

References (38)

1. [1] World Health organization (WHO). 2016. Available from: http://www.who.int/respiratory/asthma/scope/en/.
2. [2] Global Initiative for Asthma, Global Strategy for Asthma Management and Prevention. 2016 Available from: www.ginasthma.org.
3. [3] Cottini, M., Asero, R., Asthma phenotypes today. Eur. Ann. Allergy Clin. Immunol. 45 (2013), 17–24.
4. [4] Lotvall, J., Akdis, C.A., Bacharier, L.B., Bjermer, L., Casale, T.B., Custovic, A., et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J. Allergy Clin. Immunol. 127 (2011), 355–360.
5. [5] Bateman, E.D., The economic burden of uncontrolled asthma across Europe and the Asia-Pacific region: can we afford to not control asthma?. Eur. Respir. Rev. 15 (2006), 1–3.
6. [6] Rabe, K.F., Adachi, M., Lai, C.K., Soriano, J.B., Vermeire, P.A., Weiss, K.B., et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J. Allergy Clin. Immunol. 114 (2004), 40–47.
7. [7] Gamble, J., Stevenson, M., McClean, E., Heaney, L.G., The prevalence of nonadherence in difficult asthma. Am. J. Respir. Crit. Care Med. 180 (2009), 817–822.
8. [8] Barnes, P.J., New therapies for asthma: is there any progress?. Trends Pharmacol. Sci. 31 (2010), 335–343.
9. [9] Lewis, R.A., Soter, N.A., Diamond, P.T., Austen, K.F., Oates, J.A., Roberts, L.J. 2nd, Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J. Immunol. 129 (1982), 1627–1631.
10. [10] Urade, Y., Ujihara, M., Horiguchi, Y., Ikai, K., Hayaishi, O., The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J. Immunol. 143 (1989), 2982–2989.
11. [11] Tanaka, K., Ogawa, K., Sugamura, K., Nakamura, M., Takano, S., Nagata, K., Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets. J. Immunol. 164 (2000), 2277–2280.
12. [12] Matsuoka, T., Hirata, M., Tanaka, H., Takahashi, Y., Murata, T., Kabashima, K., et al. Prostaglandin D2 as a mediator of allergic asthma. Science 287 (2000), 2013–2017.
13. [13] Murray, J.J., Tonnel, A.B., Brash, A.R., Roberts, L.J. 2nd, Gosset, P., Workman, R., et al. Release of prostaglandin D2 into human airways during acute antigen challenge. N. Engl. J. Med. 315 (1986), 800–804.
14. [14] Pettipher, R., The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br. J. Pharmacol. 153:Suppl. 1 (2008), S191–S199.
15. [15] Cheng, K., Wu, T.J., Wu, K.K., Sturino, C., Metters, K., Gottesdiener, K., et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 6682–6687.
16. [16] Hirai, H., Tanaka, K., Yoshie, O., Ogawa, K., Kenmotsu, K., Takamori, Y., et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 193 (2001), 255–261.
17. [17] Xue, L., Gyles, S.L., Wettey, F.R., Gazi, L., Townsend, E., Hunter, M.G., et al. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J. Immunol. 175 (2005), 6531–6536.
18. [18] Pettipher, R., Hansel, T.T., Armer, R., Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug Discov. 6 (2007), 313–325.
19. [19] Snell, N.J., Discontinued drug projects in the respiratory therapeutic area during 2012. Expert Opin. Investig. Drugs 23 (2014), 411–415.
20. [20] Norman, P., Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin. Investig. Drugs 23 (2014), 55–66.
21. [21] Luu, V.T., Goujon, J.Y., Meisterhans, C., Frommherz, M., Bauer, C., Synthesis of a high specific activity methyl sulfone tritium isotopologue of fevipiprant (NVP-QAW039). J. Label. Compd. Radiopharm. 58 (2015), 188–195.
22. [22] Erpenbeck, V.J., Vets, E., Gheyle, L., Osuntokun, W., Larbig, M., Neelakantham, S., et al. Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects. Eur. Respir. J., 44, 2014.
23. [23] Willard, L., Brown, Z., Owen, C., Dubois, G., Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists. Eur. Respir. J., 44, 2014.
24. [24] Gonem, S., Berair, R., Singapuri, A., Hartley, R., Laurencin, M., Bacher, G., et al. Late-breaking abstract: phase 2a randomized placebo-controlled trial of the oral prostaglandin D2 receptor (DP2/CRTh2) antagonist QAW039 in eosinophilic asthma. Eur. Respir. J., 44, 2014.
25. [25] Erpenbeck, V.J., Vets, E., Gheyle, L., Osuntokun, W., Larbig, M., Neelakantham, S., et al. Pharmacokinetics, safety, and tolerability of fevipiprant (QAW039), a novel CRTh2 receptor antagonist: results from 2 randomized, phase 1, placebo-controlled studies in healthy volunteers. Clin. Pharmacol. Drug Dev. 5:4 (2016), 306–313.
26. [26] Global Initiative for Asthma, Global Strategy for Asthma Management and Prevention. 2009 Available from: www.ginasthma.org.
27. [27] Makela, M.J., Backer, V., Hedegaard, M., Larsson, K., Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir. Med. 107 (2013), 1481–1490.
28. [28] Barnes, P.J., Pedersen, S., Busse, W.W., Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Respir. Crit. Care Med. 157 (1998), S1–S53.
29. [29] Hall, I.P., Fowler, A.V., Gupta, A., Tetzlaff, K., Nivens, M.C., Sarno, M., et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm. Pharmacol. Ther. 32 (2015), 37–44.
30. [30] Busse, W.W., Wenzel, S.E., Meltzer, E.O., Kerwin, E.M., Liu, M.C., Zhang, N., et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J. Allergy Clin. Immunol. 131 (2013), 339–345.
31. [31] Barnes, N., Pavord, I., Chuchalin, A., Bell, J., Hunter, M., Lewis, T., et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol. 42 (2012), 38–48.
32. [32] Rothwell, P.M., Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365 (2005), 176–186.
33. [33] Price, D., Fletcher, M., van der Molen, T., Asthma control and management in 8,000 European patients: the REcognise asthma and LInk to symptoms and experience (REALISE) survey. NPJ Prim. Care Respir. Med., 24, 2014, 14009.
34. [34] Vennera, M.D., Picado, C., Herraez, L., Galera, J., Casafont, J., en nombre del Grupo de Estudio C. Factors associated with severe uncontrolled asthma and the perception of control by physicians and patients. Arch. Bronconeumologia 50 (2014), 384–391.
35. [35] Pettipher, R., Hunter, M.G., Perkins, C.M., Collins, L.P., Lewis, T., Baillet, M., et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy 69 (2014), 1223–1232.
36. [36] Wenzel, S.E., Hopkins, R., Saunders, M., Chantry, D., Anderson, L., Aitchison, R., et al. Safety and efficacy of ARRY-502, a potent, selective, oral CRTh2 antagonist, in patients with mild to moderate Th2-Driven asthma. J. Allergy Clin. Immunol., 133, 2014, AB4.
37. [37] Sykes, D.A., Bradley, M.E., Riddy, D.M., Willard, E., Reilly, J., Miah, A., et al. Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy. Mol. Pharmacol. 89 (2016), 593–605.
38. [38] Rachid, B., Sherif, G., Amisha, S., Ruth, H., Marie, L., Gerald, B., et al. Effect of QAW039, an oral prostaglandin D2 receptor (DP2/CRTh2) antagonist, upon sputum and bronchial eosinophilic inflammation and clinical outcomes in treatment-resistant asthma: a phase 2a randomized placebo-controlled trial. Am. Thorac. Soc., 2015, A6361-A.